Related Experiment Video

Updated: Mar 19, 2026

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

14.0K

Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer

Junli Deng1,2,3,4, Li Wang3,4, Hongmin Chen3,4

  • 1Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.

Oncotarget
|June 16, 2016
PubMed

Insights

Chemoresistance in recurrent ovarian cancer is a major hurdle. Targeting epithelial-mesenchymal transition and cancer stem cells offers promising therapeutic strategies for improved patient survival.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Chemoresistance presents a significant challenge in recurrent ovarian cancer, leading to treatment failure and poor clinical outcomes.
  • Understanding chemoresistance mechanisms is crucial for predicting disease progression and personalizing therapy.
  • Epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) are increasingly recognized for their roles in ovarian cancer chemoresistance and metastasis.

Purpose of the Study:

  • To review the critical roles of EMT and CSCs in ovarian cancer chemoresistance.
  • To explore the therapeutic implications of targeting EMT and CSCs for future ovarian cancer treatment strategies.

Main Methods:

  • This review synthesizes current research findings on EMT and CSCs in ovarian cancer.
  • Literature search focused on studies investigating mechanisms of chemoresistance and therapeutic interventions.

Main Results:

  • Accumulating evidence highlights EMT and CSCs as key drivers of chemoresistance and metastasis in ovarian cancer.
  • Targeting EMT and CSCs demonstrates potential for overcoming treatment resistance.

Conclusions:

  • EMT and CSCs are pivotal in ovarian cancer chemoresistance and metastasis.
  • Therapeutic strategies targeting EMT and CSCs hold promise for enhancing current ovarian cancer treatments and improving patient survival in recurrent disease.
Keywords:
CSCEMTchemoresistanceovarian cancertherapy

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.9K

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K